Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Buys 15,100 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 15,100 shares of the stock in a transaction dated Tuesday, January 6th. The shares were bought at an average price of $19.89 per share, for a total transaction of $300,339.00. Following the transaction, the insider owned 989,893 shares in the company, valued at approximately $19,688,971.77. This represents a 1.55% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, December 5th, Group Gp Lp Column III bought 30,884 shares of Surrozen stock. The shares were acquired at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The shares were purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The stock was bought at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Trading Down 4.6%

SRZN opened at $19.06 on Friday. The company has a market cap of $163.34 million, a price-to-earnings ratio of -0.85 and a beta of 0.58. The company’s 50 day moving average is $17.88 and its 200 day moving average is $13.47. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million during the quarter. As a group, analysts predict that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Surrozen

Several institutional investors have recently added to or reduced their stakes in the business. Stempoint Capital LP increased its stake in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after purchasing an additional 445,713 shares during the period. Braidwell LP purchased a new stake in Surrozen in the 2nd quarter valued at approximately $1,252,000. Woodline Partners LP purchased a new position in shares of Surrozen during the 3rd quarter worth approximately $621,000. Millennium Management LLC acquired a new stake in shares of Surrozen in the 3rd quarter valued at approximately $1,414,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen in the 3rd quarter valued at approximately $889,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SRZN. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Surrozen has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.